The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma

Published:2020-08-02 Issue:8 Volume:20 Page:687-701
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

McClure Erin¹,Carr Michael J²^ORCID,Zager Jonathan S²³^ORCID

Affiliation:

1. University of South Florida Morsani College of Medicine, Tampa, FL, USA

2. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

3. Department of Oncological Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1796646

Reference110 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

4. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy;Journal of Experimental & Clinical Cancer Research;2024-01-23

2. Augmenting MEK inhibitor Efficacy in BRAF Wild-Type Melanoma: Synergistic Effects of Disulfiram Combination Therapy;2023-08-23

3. Discovery of β-cyclocitral-derived mono-carbonyl curcumin analogs as anti-hepatocellular carcinoma agents via suppression of MAPK signaling pathway;Bioorganic Chemistry;2023-03

4. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma;Biomolecules;2022-10-26

5. In-transit metastatic cutaneous melanoma: current management and future directions;Clinical & Experimental Metastasis;2021-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3